Literature DB >> 1355792

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

C C Peck1, W H Barr, L Z Benet, J Collins, R E Desjardins, D E Furst, J G Harter, G Levy, T Ludden, J H Rodman.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1355792     DOI： 10.1002/jps.2600810630

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  10 in total

1.  Pharmacokinetic/pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine.

Authors:  Pierre-Louis Toutain
Journal:  AAPS PharmSci       Date:  2002

2.  Fit-for-purpose method development and validation for successful biomarker measurement.

Authors:  Jean W Lee; Viswanath Devanarayan; Yu Chen Barrett; Russell Weiner; John Allinson; Scott Fountain; Stephen Keller; Ira Weinryb; Marie Green; Larry Duan; James A Rogers; Robert Millham; Peter J O'Brien; Jeff Sailstad; Masood Khan; Chad Ray; John A Wagner
Journal:  Pharm Res       Date:  2006-01-12       Impact factor: 4.200

3.  Effect of age and gender on the pharmacokinetics of grepafloxacin.

Authors:  C Efthymiopoulos; S L Bramer; A Maroli
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

4.  Correlation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein binding.

Authors:  P Aviles; C Falcoz; M J Guillén; R San Roman; F Gómez De Las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report.

Authors:  Jean W Lee; Russ S Weiner; Jeff M Sailstad; Ronald R Bowsher; Dean W Knuth; Peter J O'Brien; Jean L Fourcroy; Rakesh Dixit; Lini Pandite; Robert G Pietrusko; Holly D Soares; Valerie Quarmby; Ole L Vesterqvist; David M Potter; James L Witliff; Herbert A Fritche; Timothy O'Leary; Lorah Perlee; Sunil Kadam; John A Wagner
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

6.  Blood-brain barrier penetration of zolmitriptan--modelling of positron emission tomography data.

Authors:  Mats Bergström; Roger Yates; Anders Wall; Matts Kågedal; Stina Syvänen; Bengt Långström
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-02       Impact factor: 2.745

Review 7.  Facilitation of drug evaluation in children by population methods and modelling.

Authors:  Michel Tod; Vincent Jullien; Gérard Pons
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 8.  Paediatric labelling requirements. Implications for pharmacokinetic studies.

Authors:  J T Wilson; G L Kearns; D Murphy; S J Yaffe
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

9.  Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.

Authors:  S Dudal; K Subramanian; T Flandre; W S Law; P J Lowe; A Skerjanec; J-C Genin; M Duval; A Piequet; A Cordier; G Jarai; G Van Heeke; S Taplin; C Krantz; S Jones; A P Warren; F R Brennan; J Sims; P Lloyd
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 10.  Clinical Pharmacology of Antibody-Drug Conjugates.

Authors:  Iftekhar Mahmood
Journal:  Antibodies (Basel)       Date:  2021-05-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.